ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Molecular characterization of metallo-beta-lactamase producers among carbapenem-resistant Pseudomonas aeruginosa from clinical samples in a tertiary care hospital, Lucknow, India.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In Silico Mutational Analysis of Two-Component System Genes Associated with Colistin Resistance in ClinicalBiomolecules · 2026Article
- Retrospective study on antibiotic resistance profiles of uropathogenicFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is a significant opportunistic pathogen in healthcare-associated infections. Its intrinsic resistance and ability to acquire resistance genes pose therapeutic challenges, particularly with the emergence of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) strains. This study aimed to assess the prevalence, antimicrobial susceptibility, and metallo-β-lactamase (MBL) resistance genes (blaNDM, blaOXA48) in P. aeruginosa isolates from clinical samples over 14 months. A total of 4410 clinical samples were processed, yielding 241 non-duplicate P. aeruginosa isolates. Antimicrobial susceptibility testing (AST) identified MDR, XDR, and PDR isolates. Carbapenemase production was detected using the eCIM test, and blaNDM and blaOXA48 genes were identified via PCR. Among the 241 isolates, 128 (53.1%) were from female patients and 113 (46.9%) from males. The most common sample sources were pus 111 (46.1%), sputum 36 (14.9%), and urine 35 (14.5%). The highest prevalence was observed in the Medicine department (45, 18.7%) and TB & Chest (42, 17.4%). Inpatients contributed 126 (52.3%) isolates, while 115 (47.7%) were from outpatients. AST showed the highest sensitivity to piperacillin/tazobactam (70.2%), piperacillin (67.2%), and tobramycin (67.6%), while imipenem (47.7%) and ceftazidime (33.6%) exhibited the lowest sensitivity. MDR was identified in 88 (36.5%) isolates, XDR in 29 (12.0%), and PDR in 9 (3.7%). MDR isolates were most common in pus (33, 13.6%), while XDR and PDR were frequently found in bronchoalveolar lavage (6, 2.4%) and urine (3, 1.2%), respectively. Among 20 eCIM-positive isolates, all carried the blaNDM gene, and 17 (85.0%) harbored blaOXA48. Males accounted for 70.0% of blaNDM and 70.6% of blaOXA48 cases. The highest prevalence of blaNDM (35.0%) was in the 41-60 age group, while blaOXA48 was equally distributed between the 20-40 and 41-60 age groups (35.3% each). Sputum (25.0% blaNDM, 23.5% blaOXA48) and urine (20.0% each) were the most common specimen sources. This study demonstrates the presence of antimicrobial resistance in P. aeruginosa isolates, including MDR, XDR, and PDR strains. The detection of carbapenemase-producing isolates carrying blaNDM and blaOXA-48 genes emphasizes the importance of effective infection control measures, antimicrobial stewardship, and ongoing surveillance to monitor and manage resistance trends.
Indexed as
Identifiers
39964472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.